

Surpass® Topical Cream

Common Drug Name – Diclofenac

How Supplied from SmartPak – Surpass is available in a 124gram tube.

Category –Diclofenac is a nonsteroidal antiinflammatory (NSAID) of the phenylacetic acid class.

Caution - Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indications (Uses) – Surpass is for the control of pain and inflammation associated with osteoarthritis in hock, knee, fetlock and pastern joints in horses.

Dosage and Administration – Apply a five-inch (5") ribbon of Surpass twice daily over the affected joint for up to 10 days. Wear rubber gloves to prevent absorption into the hands. Rub the cream thoroughly into the hair covering the joint until it disappears.

Warning – Not for horses intended for human consumption. For topical use in horses only.

Human Warning – Not for human use. Keep out of the reach of children. Consult a physician in case of accidental ingestion by humans. Direct contact with the skin should be avoided. If contact occurs. The skin should be washed immediately with soap and water.

Contraindications – Surpass is contraindicated in animals with known hypersensitivity to Diclofenac.

Precautions – Exceeding the recommended dosage or treating multiple joints may

increase plasma concentrations of diclofenac. Horses should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests should be conducted to establish hematological and serum biochemical baseline data before and periodically during administration of any NSAID. Treatment with Surpass should be terminated if signs such as inappetence, colic, fecal abnormalities, anemia or depression are observed. As a class, NSAIDs may be associated with GI and renal toxicity. When NSAIDS inhibit prostaglandins that cause inflammation, they may also inhibit prostaglandins that maintain normal homeostatic function. These antiprostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease more often than in healthy patients. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal cardiovascular and/or hepatic dysfunction. Since many NSAIDs possess the potential to induce gastric ulceration, concomitant use of Surpass with any other anti-influmatory drugs, such as other NSAIDs and corticosteroids, should be avoided. The safety of Surpass has not been investigated in breeding, pregnant or lactating horses, or in horses under one year of age.

Adverse Reactions (Side Effects) -

Adverse reactions may include weight loss, colic, diarrhea or icterus. Serious adverse reactions associated with this drug class can occur without warning and, in rare situations, result in dealth. Owners should discontinue NSAID therapy and contact their veterinarian immediately if signs of intolerance are observed. **Storage Conditions**: Store up to 77F. Protect from freezing.

Manufactured for:

IDEXX Pharmaceuticals, Inc. Greensboro, NC 27410

Rev. 1/08

SmartPak 40 Grissom Road, Suite 500 Plymouth, MA 02360 Phone: 1-800-431-4194 Fax: 1-800-431-4179 www.SmartPak.com